News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Phytopharm PLC (PYM.L) Stopping R&D Spending, Cutting Headcount


3/26/2013 7:36:05 AM

Drug development company, Phytopharm, has begun talks with potential buyers for the company after it confirmed the results of its Phase II clinical trial of Cogane in Parkinson's disease, which showed that the drug had demonstrated no clinically meaningful efficacy. Those results were first announced in February, sparking a massive sell off in the company's stock which now trades at just over a tenth of its then price. Today's announcement that exploratory discussions have been held with a number of parties regarding a potential merger or acquisition however added 3.33 per cent to its price, which is now at 1.55 pence a share.

Read at News Release
Read at Share Cast
Read at News Release
Read at Reuters


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES